16841-84-2 Usage
Uses
Used in Pharmaceutical Development:
5-methoxy-1,3,4-thiadiazol-2-amine is used as a key intermediate in the synthesis of various pharmaceuticals for its potential therapeutic effects. The presence of the thiadiazole ring and the amine group allows for the development of drugs with specific biological activities, targeting a range of medical conditions.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 5-methoxy-1,3,4-thiadiazol-2-amine serves as a building block for designing new molecules with improved pharmacological properties. Its structural features can be exploited to create compounds with enhanced solubility, bioavailability, and potency, which are crucial for effective drug action.
Used in Drug Delivery Systems:
5-methoxy-1,3,4-thiadiazol-2-amine can be utilized in the development of drug delivery systems to improve the efficacy and safety of therapeutic agents. Its chemical properties may facilitate the creation of targeted drug delivery platforms, enhancing the bioavailability and reducing side effects of medications.
Used in Chemical Research:
As a member of the thiadiazole class, 5-methoxy-1,3,4-thiadiazol-2-amine is used in chemical research to explore new reactions and synthetic pathways. Understanding its reactivity and potential interactions with other molecules can lead to the discovery of novel compounds with unique applications in various industries.
Used in Agrochemicals:
5-methoxy-1,3,4-thiadiazol-2-amine may also find applications in the agrochemical industry, where it could be used as a component in the development of new pesticides or herbicides. Its biological activity and chemical properties make it a candidate for creating effective and environmentally friendly agricultural products.
Check Digit Verification of cas no
The CAS Registry Mumber 16841-84-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,8,4 and 1 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 16841-84:
(7*1)+(6*6)+(5*8)+(4*4)+(3*1)+(2*8)+(1*4)=122
122 % 10 = 2
So 16841-84-2 is a valid CAS Registry Number.
16841-84-2Relevant academic research and scientific papers
Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy
Miller, Michael M.,Banville, Jacques,Friends, Todd J.,Gagnon, Mark,Hangeland, Jon J.,Lavallée, Jean-Fran?ois,Martel, Alain,O'Grady, Harold,Rémillard, Roger,Ruediger, Edward,Tremblay, Fran?ois,Posy, Shana L.,Allegretto, Nick J.,Guarino, Victor R.,Harden, David G.,Harper, Timothy W.,Hartl, Karen,Josephs, Jonathan,Malmstrom, Sarah,Watson, Carol,Yang, Yanou,Zhang, Ge,Wong, Pancras,Yang, Jing,Bouvier, Michel,Seiffert, Dietmar A.,Wexler, Ruth R.,Lawrence, R. Michael,Priestley, E. Scott,Marinier, Anne
, p. 7400 - 7416 (2019/08/26)
In an effort to identify novel antithrombotics, we have investigated protease-activated receptor 4 (PAR4) antagonism by developing and evaluating a tool compound, UDM-001651, in a monkey thrombosis model. Beginning with a high-throughput screening hit, we identified an imidazothiadiazole-based PAR4 antagonist chemotype. Detailed structure-activity relationship studies enabled optimization to a potent, selective, and orally bioavailable PAR4 antagonist, UDM-001651. UDM-001651 was evaluated in a monkey thrombosis model and shown to have robust antithrombotic efficacy and no prolongation of kidney bleeding time. This combination of excellent efficacy and safety margin strongly validates PAR4 antagonism as a promising antithrombotic mechanism.
IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
-
Paragraph 00131, (2013/11/18)
The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, Rx, R1, R2, R3, X1, X2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.
